Related Experiment Video
Updated: May 13, 2026
09:24
Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
Published on: August 22, 2017
FVIII half-life products: A real-world experience.
Ezio Zanon1, Annamaria Porreca2, Angela Napolitano3
1Haemophilia Center, First Chair of Internal Medicine, Via Giustiniani 2, University Hospital of Padua, 35128 Padua, Italy.
Thrombosis Research
|March 27, 2025
Summary
Extended half-life Factor VIII (FVIII) products significantly reduce infusion frequency in haemophilia A patients. These advanced treatments maintain effective bleeding control, improving patient adherence and quality of life.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Haemophilia A is a genetic bleeding disorder requiring Factor VIII (FVIII) replacement therapy.
- Prophylactic FVIII treatment is crucial for preventing joint damage and improving quality of life.
- Extended half-life (EHL) FVIII products offer advancements in treatment frequency, efficacy, and safety.
Purpose of the Study:
- To evaluate the real-world utilization and effectiveness of FVIII products.
- To compare pharmacokinetic profiles and infusion frequencies of EHL FVIII products versus standard half-life (SHL) products.
- To assess bleeding control and treatment burden in patients receiving EHL FVIII therapy.
Main Methods:
- A single-centre observational study conducted from January 2018 to December 2023.
- Involved 124 male patients treated at the Haemophilia Centre of Padua.
- Analysis of patient characteristics, treatment regimens, and pharmacokinetic data.
Main Results:
- Esperoct® demonstrated the longest median half-life (19.75 hours), followed by Elocta® (16.50 hours) and Jivi® (15.38 hours).
- EHL FVIII products resulted in significantly lower weekly infusion rates (1.4) compared to SHL products (2.0) (p < 0.001).
- Comparable bleeding control was observed across different EHL FVIII products.
Conclusions:
- EHL FVIII products provide substantial clinical benefits by reducing infusion burden and enhancing adherence.
- Effective bleeding control is maintained with EHL FVIII therapies.
- Further research on cost, safety, and long-term outcomes is necessary for optimal integration into haemophilia care.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Related Concept Videos
02:42Half-life of a Reaction
The half-life of a reaction (t1/2) is the time required for one-half of a given amount of reactant to be consumed. In each succeeding half-life, half of the remaining concentration of the reactant is consumed. For example, during the decomposition of hydrogen peroxide, during the first half-life (from 0.00 hours to 6.00 hours), the concentration of H2O2 decreases from 1.000 M to 0.500 M. During the second half-life (from 6.00 hours to 12.00 hours), the concentration decreases from 0.500 M to...
02:48Radioactive Decay and Radiometric Dating
Radioactivity is a spontaneous disintegration of an unstable nuclide and is a random process, as all the nuclei in the sample do not decay simultaneously. The number of disintegrations per unit time is called the activity (A), which is directly proportional to the number of nuclei in the sample. The decay constant (λ) is an average probability of decay per nucleus in unit time.
01:09One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated from...
01:18Two-Compartment Open Model: IV Bolus Administration
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
The disparity between drug input and the sum of drug transfer rates between...
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.